May 19, 2008 -- Oculus Innovative Sciences (NSDQ: OCLS) of Petaluma, CA has firmed up a plan for commercializing its Microcyn® products in China, following SFDA approval two months ago. Oculus’ China distribution partner, China Bao Tai, will distribute samples of Microcyn to key opinion leaders, asking them to test the clinical effect of the product by conducting post-approval trials. The data will be used to help secure reimbursement from insurance institutions. More details...
